Oxford BioDynamics ( (GB:OBD) ) just unveiled an update.
Oxford BioDynamics Plc announced the successful passing of all resolutions at its Annual General Meeting. This development underscores the company’s continued commitment to advancing precision medicine through its innovative diagnostic tests, potentially enhancing its market position and stakeholder confidence.
More about Oxford BioDynamics
Oxford BioDynamics Plc is an international biotechnology company that specializes in precision clinical diagnostics. The company develops and commercializes diagnostic tests for life-changing diseases using its proprietary EpiSwitch® 3D genomics platform. Their products include the EpiSwitch® PSE for prostate cancer and EpiSwitch® CiRT for immuno-oncology treatments. OBD is headquartered in Oxford, UK, with operations in the US and Malaysia, and is listed on the London Stock Exchange’s AIM.
YTD Price Performance: -68.33%
Average Trading Volume: 20,680,224
Technical Sentiment Signal: Buy
Current Market Cap: £9.3M
See more insights into OBD stock on TipRanks’ Stock Analysis page.